GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
* Meda exceeds published full-year forecast for 2010.
* Group sales reach SEK 11,571 million (13,178). Currency effects and generic competition for the Astelin and Optivar products are the most important reasons for decreased sales compared with last year.
* EBITDA amounts to SEK 4,306 million (4,387), corresponding to a 37.2% margin (33.3).
